Please assess the completion status of the following clinical trial:

Trial Title: Pilot of Preemptive Pharmacogenetics in Medically Underserved Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (18 years or older) with active prescriptions for at least 3 medications documented within the EHR.~* At least 1 drug/drug class that could be informed by the pharmacogenetics test panel available at the UF.~* A medication change within the past 6 months (associated with a healthcare provider encounter).~* Self-identify as black or Latino.~Exclusion Criteria:~* Patients with any history of pharmacogenetic testing within the EHR.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Panel-based pharmacogenetic genotyping (Type: EXPERIMENTAL): All patients will receive clinical preemptive pharmacogenetic testing. Genotype results and consult notes will returned in the EHR pre-emptively. Data on implementation success metrics and PROs via patient report and TSQM measures will be collected. In addition, data on effectiveness outcomes and socioeconomic measures will be collected via the EHR and patient report, respectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).